Worldwide, exclusive licensing deal covering gastrin compounds could yield another $130 million in milestones.



Transition Therapeutics could reap over $137 million through a collaboration with Eli Lilly covering diabetes compounds. Eli Lilly will initially pay $7 million for the exclusive, worldwide rights to Transition’s gastrin-based therapeutic portfolio.


The agreement includes TT-223, which is in early clinical development. The candidate is being evaluated in combination with an EGF analogue and a GLP-1 analogue in type 1/2 diabetes as well as metformin in type 2 diabetes. Transition and Lilly will jointly conduct the planned Phase II study in type 2 diabetes. Thereafter, Lilly will be responsible for development and commercialization of all gastrin-based therapeutic products worldwide.


Gastrin-based therapies provide sustained improvement in glycemic control in preclinical models and early clinical studies, according to the firms.








This site uses Akismet to reduce spam. Learn how your comment data is processed.